Fly News Breaks for March 10, 2015
ACT, AKRX
Mar 10, 2015 | 08:59 EDT
Needham believes Actavis's (ACT) launch of a generic clobetasol cream will likely cost Akorn (AKRX) 10c-12c of annualized earnings per share, which it feels diminishes the upside numbers case. The firm says the news does not derail Akorn's growth story, however. It keeps a Hold rating on the name.
News For AKRX;ACT From the Last 2 Days
There are no results for your query AKRX;ACT